docetaxel anhydrous and tamoxifen
docetaxel anhydrous has been researched along with tamoxifen in 65 studies
Compound Research Comparison
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (tamoxifen) | Trials (tamoxifen) | Recent Studies (post-2010) (tamoxifen) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 20,630 | 2,227 | 6,256 |
Protein Interaction Comparison
Research
Studies (65)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (6.15) | 18.2507 |
2000's | 26 (40.00) | 29.6817 |
2010's | 30 (46.15) | 24.3611 |
2020's | 5 (7.69) | 2.80 |
Authors
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
Verlag, GT | 1 |
Benedetti Panici, P; Bombardelli, E; Distefano, M; Fattorossi, A; Ferlini, C; Filippini, P; Isola, G; Mancuso, S; Riva, A; Scambia, G | 1 |
Gradishar, WJ | 1 |
Beijnen, JH; Crommentuyn, KM; Schellens, JH; van den Berg, JD | 1 |
Nelson, NJ | 1 |
Takatsuka, Y | 1 |
Ames, FC; Breslin, TM; Buzdar, AU; Cohen, L; Delpassand, ES; Feig, BW; Fleming, JB; Hortobagyi, GN; House, R; Hunt, KK; Kuerer, HM; Newman, LA; Ross, MI; Sahin, A; Singletary, SE | 1 |
Blohmer, JU; Costa, SD; Eidtmann, H; Eiermann, W; Gademann, G; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; Tulusan, AH; von Minckwitz, G | 1 |
Leyland-Jones, B; Smith, I | 1 |
Oka, M; Saito, K; Takano, N; Tangoku, A | 1 |
Blohmer, JU; Caputo, A; Costa, SD; du Bois, A; Eidtmann, H; Gademann, G; Gerber, B; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Sinn, HP; Tulusan, AH; von Minckwitz, G | 1 |
Hensley, ML | 1 |
Mokbel, K; Singh-Ranger, G | 1 |
Haritoglou, C; Mueller, AJ | 1 |
Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D | 1 |
Aebersold, DM; Altermatt, HJ; Berclaz, G; Djonov, V; Greiner, RH; Gruber, G; Hlushchuk, R | 1 |
Accurso, A; Cancello, G; Caputo, F; De Laurentiis, M; De Placido, S; Esposito, A; Giordano, A; Giuliano, M; Malorni, L; Montagna, E; Pennacchio, R; Silvestro, L; Zinno, L | 1 |
Aumiller, J | 1 |
Fujiuchi, N; Okubo, K; Saeki, T; Takeuchi, H | 1 |
Asselain, B; Bonneterre, J; Campone, M; Canon, JL; Delozier, T; Eichler, F; Ferrero, JM; Fumoleau, P; Genève, J; Goudier, MJ; Kerbrat, P; Martin, AL; Monnier, A; Roché, H; Serin, D; Soulié, P; Spielmann, M; Symann, M; Viens, P; Vindevoghel, A | 1 |
Marsh, S; McLeod, HL | 1 |
Bergström, M; Blomqvist, C; Carlsson, J; Josephsson, R; Långström, B; Monazzam, A | 1 |
Andersson, M; Balil, A; Bendahmane, B; Buyse, M; Castiglione-Gertsch, M; Crown, J; Di Leo, A; Dolci, S; Francis, P; Gelber, RD; Goldhirsch, A; Gutiérrez, J; Jakesz, R; Jamin, S; Lang, I; Nordenskjöld, B; Piccart-Gebhart, M; van Hazel, G; Vorobiof, D | 1 |
Collingridge, D | 1 |
Czeczuga-Semeniuk, E; Lemancewicz, D; Wolczyński, S | 1 |
Cecchini, RS; Costantino, JP; Ganz, PA; Land, SR; Mamounas, EP; Ritter, MW; Swain, SM; Wolmark, N | 1 |
Blohmer, JU; Caputo, A; Costa, SD; Eidtmann, H; Hilfrich, J; Jackisch, C; Kaufmann, M; Loibl, S; Merkle, E; Raab, G; Sinn, HP; von Minckwitz, G | 1 |
Anderssona, M; Awadab, A; Barrett-Leec, P; Ellisd, P; Hupperetse, P; Jackischf, C; Kubistag, E; Lückh, HJ; Monnerati, C; Nitzj, U; Untchl, M | 1 |
Azzouz, F; Borges-Gonzales, S; Desta, Z; Flockhart, DA; Jason, RD; Li, L; McLeod, HL; Nguyen, A; Shen, C; Skaar, T; Sweeney, CJ; Yu, M | 1 |
Cheang, MC; Dumontet, C; Hanson, J; Hugh, J; Krajewska, M; Mackey, J; Magherini, E; Martin, M; Nielsen, TO; Perou, CM; Reed, J; Rupin, M; Treilleux, I; Vogel, C | 1 |
Ajarim, DS; Al-Malik, OA; Al-Tweigeri, TA; Alsayed, AA; Alshabanah, MO; El-Husseiny, GA; Elkum, NB; Ezzat, AA; Fatani, DM; Rahal, MM; Tulbah, AM | 1 |
Arima, N; Hayashi, M; Nishimura, R; Okumura, Y; Osako, T | 1 |
Chen, L; Dai, JC; Ling, LJ; Liu, XA; Ma, JJ; Tao, AD; Wang, S; Yin, H; Zha, XM; Zhou, WB | 1 |
Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
Aoyagi, H; Hamada, S; Hasegawa, K; Kaneko, J; Katsuta, E; Maejima, S; Ohkubo, T; Saguchi, M; Someno, Y; Takahata, T | 1 |
Atkins, JN; Cecchini, RS; Costantino, JP; Erban, JK; Fehrenbacher, L; Ganz, PA; Geyer, CE; Land, SR; Livingston, RB; Mamounas, EP; Pajon, ER; Perez, EA; Polikoff, JA; Swain, SM; Vogel, VG; Wolmark, N | 1 |
Bagot, M; Cosnes, A; Duong, TA; Gantzer, A; Ortonne, N; Regnier, S; Wolkenstein, P | 1 |
Bliss, JM; Coleman, RE; Coombes, RC; Cooper, D; den Boer, MO; Erdkamp, F; Espie, M; Hupperets, P; Kilburn, LS; Marty, M; Reise, JA; Thomas, MW; Tres, A; Tubiana-Mathieu, N; Wals, J; Wardley, A; Wilkinson, K | 1 |
Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
Bessonov, AA; Dashian, GA; Kolar'kova, VV; Paltuev, RM; Pen'kov, KD; Remizov, AS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
Ayadi, M; Boussen, H; Chraiet, N; Gligorov, J; Krimi, S; Labidi, S; Lagha, A | 1 |
Accolla, ML; Castelli, F; Celia, C; Ferrari, M; Fresta, M; Grattoni, A; Paolino, D; Sarpietro, MG | 1 |
Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
Ng, CH; Rozita, AM; Taib, NA; Tiong, V; Yip, CH | 1 |
Bayly, C; Cheung, KC; Grist, SM; Ni, C; Yu, L | 1 |
Havrankova, J; Hofman, J; Skarka, A; Wsol, V | 1 |
Kulkarni, AB; Liu, B; Sun, ZJ; Wang, YF; Zhang, L; Zhang, W; Zhang, WF; Zhao, YF | 1 |
Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R | 1 |
Fu, X; Guo, C; He, L; Hu, X; Li, G; Pan, R; Wen, S; Zhang, X; Zhao, C | 1 |
Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P | 1 |
Attar, HE; Belkheiri, S; Benchakroun, N; Benider, A; Bennani, Z; Bouchbika, Z; Jouhadi, H; Safini, F; Sahraoui, S; Tawfiq, N | 1 |
Li, Y; Pan, H; Pan, W; Yang, X; Zhu, Z | 1 |
Bernard-Marty, C; Dalenc, F; de Lafontan, B; Dulguerova, P; Guerrero, D; Guyonnaud, J; Levasseur, N; Levecq, JM; Massabeau, C; Ranc Royo, AL; Ribet, V; Rossi, AB; Salas, S; Sarda, C; Sibaud, V | 1 |
Dalenc, F; Roché, H; Sarradin, V; Sibaud, V; Tournier, E | 1 |
Ingle, JN; Liu, M; Qin, S; Shen, K; Wang, G; Wang, L; Weinshilboum, RM; Zayas, J | 1 |
Li, Y; Pan, H; Pan, W; Zhu, Z | 1 |
Anazodo, A; Dickinson, JE; Li, Z; Lui, K; Safi, N; Sullivan, EA; Wang, AY | 1 |
Coonrod, SA; Li, F; Liu, X; Miao, L; Mondal, S; Qin, H; Thompson, PR; Xue, T; Zhang, X | 1 |
Cheng, L; Li, L; Lu, Y; Majumdar, A; Stover, D; Wu, S | 1 |
Albain, KS; Carlos, RC; Cella, D; Dees, EC; Garcia, SF; Geyer, CE; Goetz, MP; Gray, RJ; Hayes, DF; McCaskill-Stevens, WJ; Minasian, LM; Olson, JA; Pritchard, KI; Sledge, GW; Sparano, JA; Tevaarwerk, AJ; Wagner, LI; Whelan, TJ; Yanez, B | 1 |
Etminan, M; Maberley, D; Mikelberg, F; Sodhi, M; Yeung, SN | 1 |
Fei, S; Gu, J; Li, N; Liu, X; Thompson, PR; Xue, T; Zhang, P; Zhang, X | 1 |
Reviews
13 review(s) available for docetaxel anhydrous and tamoxifen
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Progress and perspectives in palliative therapy of breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Goserelin; Humans; Paclitaxel; Palliative Care; Tamoxifen; Taxoids | 1996 |
In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.
Topics: Animals; Antineoplastic Agents; Cytochrome P-450 Enzyme System; Docetaxel; Drug Interactions; Humans; Ifosfamide; Models, Chemical; Paclitaxel; Species Specificity; Tamoxifen; Taxoids; Tumor Cells, Cultured | 1998 |
[Neoadjuvant chemotherapy for locally advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Premedication; Tamoxifen; Taxoids | 2000 |
Role of Herceptin in primary breast cancer: views from North America and Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Interactions; Europe; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; North America; Paclitaxel; Palliative Care; Pilot Projects; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Safety; Survival Analysis; Tamoxifen; Taxoids; Trastuzumab; Treatment Outcome | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab | 2005 |
[Current status of adjuvant chemotherapy for breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Menopause; Perioperative Care; Tamoxifen; Taxoids; Trastuzumab | 2006 |
Pharmacogenetics and oncology treatment for breast cancer.
Topics: Aromatase Inhibitors; Biological Transport; Breast Neoplasms; Cytochrome P-450 CYP2D6; Docetaxel; Female; Gene Amplification; Genes, bcl-1; Glucuronosyltransferase; Humans; Paclitaxel; Pharmacogenetics; Tamoxifen; Taxoids | 2007 |
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Neoplasms; Paclitaxel; Receptors, Notch; Signal Transduction; Tamoxifen; Taxoids; Trastuzumab | 2010 |
[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Topics: Adenocarcinoma; Aged; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Mastectomy; Middle Aged; Paclitaxel; Paraneoplastic Syndromes; Ribonucleoproteins; Salvage Therapy; Tamoxifen; Taxoids; Trastuzumab | 2011 |
[Impact of taxanes in the adjuvant setting of node-negative breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Paclitaxel; Tamoxifen; Taxoids | 2013 |
Trials
14 trial(s) available for docetaxel anhydrous and tamoxifen
Article | Year |
---|---|
Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Doxorubicin; Drug Administration Schedule; Estrogen Antagonists; Female; Fever; Humans; Infusions, Intravenous; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Tamoxifen; Taxoids | 1997 |
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids | 2000 |
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Patient Compliance; Preoperative Care; Prospective Studies; Tamoxifen; Taxoids | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Tamoxifen; Taxoids; Treatment Outcome | 2006 |
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Odds Ratio; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Taxoids; Treatment Outcome | 2008 |
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Premenopause; Quality of Life; Reproductive History; Surveys and Questionnaires; Survival Rate; Tamoxifen; Taxoids; Young Adult | 2009 |
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Logistic Models; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2008 |
Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Doxorubicin; Estrogens; Female; Genes, erbB-2; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Progesterone; Prospective Studies; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Treatment Outcome; Young Adult | 2010 |
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Menstruation; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires; Survival Rate; Tamoxifen; Taxoids; Treatment Outcome | 2011 |
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Second Primary; Quality of Life; Selective Estrogen Receptor Modulators; Tamoxifen; Taxoids | 2011 |
Efficacy of tamoxifen in combination with docetaxel in patients with advanced non-small-cell lung cancer pretreated with platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Tamoxifen; Taxoids | 2016 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Decision-Making; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy, Segmental; Middle Aged; Molecular Typing; Neoadjuvant Therapy; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen; Taxoids; Treatment Outcome; Triazoles; Young Adult | 2017 |
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Emollients; Epirubicin; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Hand-Foot Syndrome; Humans; Hydrotherapy; Hyperpigmentation; Lymphedema; Manual Lymphatic Drainage; Massage; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pruritus; Quality of Life; Radiodermatitis; Radiotherapy, Adjuvant; Skin Care; Skin Diseases; Tamoxifen; Taxoids | 2018 |
Other Studies
39 other study(ies) available for docetaxel anhydrous and tamoxifen
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; DNA Fragmentation; DNA, Neoplasm; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; G2 Phase; Humans; Paclitaxel; Receptors, Estrogen; Tamoxifen; Taxoids; Tumor Cells, Cultured | 1997 |
Can HER2 status predict response to cancer therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Taxoids; Trastuzumab | 2000 |
[Local therapy for stage IV advanced breast cancer with brain metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Quality of Life; Radiosurgery; Tamoxifen; Taxoids | 2001 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Docetaxel; Evidence-Based Medicine; Female; Humans; Nitriles; Paclitaxel; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Technology Assessment, Biomedical; Triazoles | 2002 |
[Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Choroid Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Doxorubicin; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Paclitaxel; Pamidronate; Tamoxifen; Taxoids; Time Factors; Ultrasonography; Visual Acuity | 2003 |
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neovascularization, Pathologic; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tamoxifen; Taxoids; Triazoles; Vascular Endothelial Growth Factor A | 2004 |
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Life Tables; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Prednisone; Prognosis; Receptors, Progesterone; Risk; Survival Analysis; Tamoxifen; Taxoids; Transcription Factors; Vincristine | 2004 |
[Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Topics: Age Factors; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Humans; Mammography; Meta-Analysis as Topic; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk; Tamoxifen; Taxoids; Time Factors; Trastuzumab; Triazoles | 2006 |
Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Cell Proliferation; Docetaxel; Doxorubicin; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Ki-67 Antigen; Models, Biological; Paclitaxel; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Spheroids, Cellular; Tamoxifen; Taxoids; Tissue Distribution; Tumor Burden; Tumor Cells, Cultured | 2007 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Can vitamin A modify the activity of docetaxel in MCF-7 breast cancer cells?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carotenoids; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estradiol; Humans; Immunohistochemistry; Retinoids; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vitamin A | 2007 |
European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Tamoxifen; Taxoids; Trastuzumab | 2008 |
A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Cluster Analysis; Computer Simulation; Docetaxel; Environment; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Likelihood Functions; Logistic Models; Male; Models, Genetic; Models, Statistical; Monte Carlo Method; Pharmacogenetics; Phenotype; Prostatic Neoplasms; Reproducibility of Results; Tamoxifen; Taxoids; Treatment Outcome | 2008 |
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Taxoids | 2009 |
Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Logistic Models; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Tamoxifen; Taxoids; Tumor Suppressor Protein p53 | 2010 |
Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fertility; Fluorouracil; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Retrospective Studies; Risk Assessment; Risk Factors; Tamoxifen; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Lymph Node Excision; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Tamoxifen; Taxoids; Tegafur; Trastuzumab; Uracil | 2010 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
[The role of nanotechnology in creating novel antitumor agents].
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Design; Female; Humans; Liposomes; Nanoparticles; Nanostructures; Nanotechnology; Neoplasms; Paclitaxel; Tamoxifen; Taxoids | 2011 |
Differential scanning calorimetry as a tool to investigate the transfer of anticancer drugs to biomembrane model.
Topics: Antineoplastic Agents; Biological Transport; Calorimetry, Differential Scanning; Cell Membrane; Cold Temperature; Dimyristoylphosphatidylcholine; Docetaxel; Drug Delivery Systems; Hot Temperature; Injections; Lapatinib; Liposomes; Membranes, Artificial; Neoplasms; Phospholipids; Quinazolines; Tamoxifen; Taxoids | 2013 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles | 2013 |
Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Estradiol; Female; Fluorouracil; Follicle Stimulating Hormone; Humans; Incidence; Induction Chemotherapy; Menstruation; Middle Aged; Premenopause; Primary Ovarian Insufficiency; Prospective Studies; Retrospective Studies; Tamoxifen; Taxoids; Young Adult | 2014 |
Alginate core-shell beads for simplified three-dimensional tumor spheroid culture and drug screening.
Topics: Alginates; Cell Culture Techniques; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Equipment Design; Glucuronic Acid; Hexuronic Acids; Humans; Hydrogels; Lab-On-A-Chip Devices; MCF-7 Cells; Microspheres; Tamoxifen; Taxoids | 2015 |
Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases.
Topics: 3-Hydroxysteroid Dehydrogenases; Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductase Family 1 Member C3; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Interactions; Fluorouracil; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydroxyprostaglandin Dehydrogenases; Isoenzymes; Kinetics; Liver; MCF-7 Cells; Oxidation-Reduction; Recombinant Proteins; Tamoxifen; Taxoids | 2015 |
Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Imidazoles; In Situ Nick-End Labeling; Inhibitor of Apoptosis Proteins; Lysosomal-Associated Membrane Protein 2; Membrane Proteins; Mice; Mice, Knockout; Mice, Nude; Microtubule-Associated Proteins; Mitochondria; Naphthoquinones; Phosphorylation; Retinoblastoma Protein; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Survivin; Tamoxifen; Taxoids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Middle Aged; Nitriles; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2015 |
[Primary large cell neuroendocrine carcinoma of the breast: a rare tumor in humans].
Topics: Antineoplastic Agents; Breast Neoplasms, Male; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Docetaxel; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Tamoxifen; Taxoids; Treatment Outcome | 2016 |
The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles.
Topics: A549 Cells; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coumarins; Docetaxel; Female; Humans; Hyaluronic Acid; Male; MCF-7 Cells; Mice; Nanoparticles; Polymers; Tamoxifen; Taxoids; Thiazoles | 2017 |
Acute Generalized Exanthematous Pustulosis Induced by Docetaxel and Recurrent With Letrozole: A Case Report.
Topics: Acute Generalized Exanthematous Pustulosis; Adrenal Cortex Hormones; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Letrozole; Middle Aged; Tamoxifen; Treatment Outcome | 2018 |
4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinase Kinases; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Proteins; Tamoxifen | 2019 |
Evaluation of the Synergism Mechanism of Tamoxifen and Docetaxel by Nanoparticles.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Synergism; Erythrocytes; Estrogen Receptor alpha; Hemolysis; Humans; MCF-7 Cells; Mice; Nanoparticles; Rats; Tamoxifen; Xenograft Model Antitumor Assays | 2019 |
In utero exposure to breast cancer treatment: a population-based perinatal outcome study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Carboplatin; Case-Control Studies; Cesarean Section; Cohort Studies; Congenital Abnormalities; Continuous Positive Airway Pressure; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gestational Age; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Small for Gestational Age; Labor, Induced; New Zealand; Paclitaxel; Perinatal Death; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Premature Birth; Prospective Studies; Respiratory Distress Syndrome, Newborn; Stillbirth; Tamoxifen; Trastuzumab | 2019 |
Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Ornithine; Protein-Arginine Deiminase Type 2; Tamoxifen; Xenograft Model Antitumor Assays | 2019 |
Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine.
Topics: Breast Neoplasms; Cell Line, Tumor; Computer Simulation; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Evaluation, Preclinical; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Precision Medicine; Tamoxifen; Transcriptome | 2020 |
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognitive Dysfunction; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Tamoxifen | 2020 |
Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Child; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Macular Edema; Middle Aged; Optic Nerve Diseases; Paclitaxel; Retrospective Studies; Tamoxifen; Taxoids | 2022 |
Inhibiting MEK1 R189 citrullination enhances the chemosensitivity of docetaxel to multiple tumour cells.
Topics: Antineoplastic Agents; Citrullination; Docetaxel; Drug Resistance, Neoplasm; Humans; MAP Kinase Kinase 1; Tamoxifen | 2023 |